Oxford BioMedica PLC (OXBDF)

[marcusl2]

Uveitis

We are currently evaluating product candidates for four new ocular indications including uveitis and three undisclosed genetic retinal diseases.

By cross-referring data generated across the LentiVector® platform portfolio, we are in an increasingly strong position to develop a new wave of high value products and improve our leading intellectual property position.

We are currently evaluating product candidates for four new ocular indications, including three undisclosed genetic retinal diseases, where there is a clear unmet medical need.

For further information, please contact our Business Development team at [e-mail].

HTTP://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/uveitis-treatment-market-to-undergo-steady-growth-by-2017-with-launch-of-humira-and-xoma-052-but-unmet-needs-still-to-be-fulfilled-says-globaldata

take your pick!